Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

An Automated Microfluidic Assay for Photonic Crystal Enhanced Detection and Analysis of an Antiviral Antibody Cancer Biomarker in Serum.

Race CM, Kwon LE, Foreman MT, Huang Q, Inan H, Kesiraju S, Le P, Lim SJ, Smith AM, Zangar RC, Demirci U, Anderson KS, Cunningham BT.

IEEE Sens J. 2018 Feb 15;18(4):1464-1473. doi: 10.1109/JSEN.2017.2777529. Epub 2017 Nov 24.

2.

Susceptibility to quantum dot induced lung inflammation differs widely among the Collaborative Cross founder mouse strains.

Scoville DK, White CC, Botta D, McConnachie LA, Zadworny ME, Schmuck SC, Hu X, Gao X, Yu J, Dills RL, Sheppard L, Delaney MA, Griffith WC, Beyer RP, Zangar RC, Pounds JG, Faustman EM, Kavanagh TJ.

Toxicol Appl Pharmacol. 2015 Dec 1;289(2):240-50. doi: 10.1016/j.taap.2015.09.019. Epub 2015 Oct 21.

3.

A halotyrosine antibody that detects increased protein modifications in asthma patients.

Jin H, Hallstrand TS, Daly DS, Matzke MM, Nair P, Bigelow DJ, Pounds JG, Zangar RC.

J Immunol Methods. 2014 Jan 31;403(1-2):17-25. doi: 10.1016/j.jim.2013.11.013. Epub 2013 Dec 2.

4.

Oxidatively modified proteins as plasma biomarkers in breast cancer.

Jin H, Daly DS, Marks JR, Zangar RC.

Cancer Biomark. 2013;13(3):193-200. doi: 10.3233/CBM-130349.

5.

Diet-induced obesity reprograms the inflammatory response of the murine lung to inhaled endotoxin.

Tilton SC, Waters KM, Karin NJ, Webb-Robertson BJ, Zangar RC, Lee KM, Bigelow DJ, Pounds JG, Corley RA.

Toxicol Appl Pharmacol. 2013 Mar 1;267(2):137-48. doi: 10.1016/j.taap.2012.12.020. Epub 2013 Jan 7.

6.

Line-scanning detection instrument for photonic crystal enhanced fluorescence.

Chaudhery V, Lu M, Huang CS, Polans J, Tan R, Zangar RC, Cunningham BT.

Opt Lett. 2012 Jul 1;37(13):2565-7. doi: 10.1364/OL.37.002565.

PMID:
22743456
7.

Photonic crystal enhanced fluorescence for early breast cancer biomarker detection.

Cunningham BT, Zangar RC.

J Biophotonics. 2012 Aug;5(8-9):617-28. doi: 10.1002/jbio.201200037. Epub 2012 Jun 27. Review.

8.

High-throughput, multiplexed analysis of 3-nitrotyrosine in individual proteins.

Jin H, Zangar RC.

Curr Protoc Toxicol. 2012 Feb;Chapter 17:Unit 17.15. doi: 10.1002/0471140856.tx1715s51.

PMID:
22511115
9.

Plasma biomarkers for detecting Hodgkin's lymphoma in HIV patients.

Varnum SM, Webb-Robertson BJ, Hessol NA, Smith RD, Zangar RC.

PLoS One. 2011;6(12):e29263. doi: 10.1371/journal.pone.0029263. Epub 2011 Dec 15.

10.

Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.

Huang CS, Chaudhery V, Pokhriyal A, George S, Polans J, Lu M, Tan R, Zangar RC, Cunningham BT.

Anal Chem. 2012 Jan 17;84(2):1126-33. doi: 10.1021/ac202817q. Epub 2011 Dec 29.

11.

Reactive oxygen species alter autocrine and paracrine signaling.

Zangar RC, Bollinger N, Weber TJ, Tan RM, Markillie LM, Karin NJ.

Free Radic Biol Med. 2011 Dec 1;51(11):2041-7. doi: 10.1016/j.freeradbiomed.2011.09.001. Epub 2011 Sep 10.

12.

Reducing heterophilic antibody interference in immunoassays using single-chain antibodies.

Baird CL, Tan R, Fischer CJ, Victry KD, Zangar RC, Rodland KD.

Anal Biochem. 2011 Dec 15;419(2):333-5. doi: 10.1016/j.ab.2011.08.025. Epub 2011 Aug 30.

PMID:
21933659
13.

Smoking, COPD, and 3-nitrotyrosine levels of plasma proteins.

Jin H, Webb-Robertson BJ, Peterson ES, Tan R, Bigelow DJ, Scholand MB, Hoidal JR, Pounds JG, Zangar RC.

Environ Health Perspect. 2011 Sep;119(9):1314-20. doi: 10.1289/ehp.1103745. Epub 2011 Jun 6.

14.

Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.

Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1543-51. doi: 10.1158/1055-9965.EPI-10-1248. Epub 2011 May 17.

15.

Development of a fibrinogen-specific sandwich enzyme-linked immunosorbent assay microarray assay for distinguishing between blood plasma and serum samples.

Gonzalez RM, Zhang Q, Zangar RC, Smith RD, Metz TO.

Anal Biochem. 2011 Jul 1;414(1):99-102. doi: 10.1016/j.ab.2011.02.039. Epub 2011 Mar 1.

16.

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.

Zhang Y, Gonzalez RM, Zangar RC.

BMC Cancer. 2011 Feb 14;11:69. doi: 10.1186/1471-2407-11-69.

17.

Application of photonic crystal enhanced fluorescence to cancer biomarker microarrays.

Huang CS, George S, Lu M, Chaudhery V, Tan R, Zangar RC, Cunningham BT.

Anal Chem. 2011 Feb 15;83(4):1425-30. doi: 10.1021/ac102989n. Epub 2011 Jan 21.

18.

Analysis of high-throughput ELISA microarray data.

White AM, Daly DS, Zangar RC.

Methods Mol Biol. 2011;694:191-211. doi: 10.1007/978-1-60761-977-2_13.

PMID:
21082436
19.

Cellular recognition and trafficking of amorphous silica nanoparticles by macrophage scavenger receptor A.

Orr GA, Chrisler WB, Cassens KJ, Tan R, Tarasevich BJ, Markillie LM, Zangar RC, Thrall BD.

Nanotoxicology. 2011 Sep;5(3):296-311. doi: 10.3109/17435390.2010.513836. Epub 2010 Sep 17.

PMID:
20849212
20.

An internal calibration method for protein-array studies.

Daly DS, Anderson KK, Seurynck-Servoss SL, Gonzalez RM, White AM, Zangar RC.

Stat Appl Genet Mol Biol. 2010;9:Article 14. doi: 10.2202/1544-6115.1506. Epub 2010 Jan 27.

PMID:
20196749
21.

Protein modifications as potential biomarkers in breast cancer.

Jin H, Zangar RC.

Biomark Insights. 2009 Nov 30;4:191-200.

22.

ProMAT calibrator: A tool for reducing experimental bias in antibody microarrays.

Zangar RC, Daly DS, White AM, Servoss SL, Tan RM, Collett JR.

J Proteome Res. 2009 Aug;8(8):3937-43. doi: 10.1021/pr900247n.

PMID:
19618941
23.

High-throughput analysis of serum antigens using sandwich ELISAs on microarrays.

Servoss SL, Gonzalez R, Varnum S, Zangar RC.

Methods Mol Biol. 2009;520:143-50. doi: 10.1007/978-1-60327-811-9_10.

PMID:
19381952
24.

ELISA-BASE: an integrated bioinformatics tool for analyzing and tracking ELISA microarray data.

White AM, Collett JR, Seurynck-Servoss SL, Daly DS, Zangar RC.

Bioinformatics. 2009 Jun 15;25(12):1566-7. doi: 10.1093/bioinformatics/btp182. Epub 2009 Apr 3.

25.

Platelet proteome changes associated with diabetes and during platelet storage for transfusion.

Springer DL, Miller JH, Spinelli SL, Pasa-Tolic L, Purvine SO, Daly DS, Zangar RC, Jin S, Blumberg N, Francis CW, Taubman MB, Casey AE, Wittlin SD, Phipps RP.

J Proteome Res. 2009 May;8(5):2261-72. doi: 10.1021/pr800885j.

26.

Antibody microarrays for high-throughput, multianalyte analysis.

Jin H, Zangar RC.

Cancer Biomark. 2010;6(5-6):281-90. doi: 10.3233/CBM-2009-0140. Review.

PMID:
20938088
27.

Macrophage responses to silica nanoparticles are highly conserved across particle sizes.

Waters KM, Masiello LM, Zangar RC, Tarasevich BJ, Karin NJ, Quesenberry RD, Bandyopadhyay S, Teeguarden JG, Pounds JG, Thrall BD.

Toxicol Sci. 2009 Feb;107(2):553-69. doi: 10.1093/toxsci/kfn250. Epub 2008 Dec 10.

28.

Predicting protein concentrations with ELISA microarray assays, monotonic splines and Monte Carlo simulation.

Daly DS, Anderson KK, White AM, Gonzalez RM, Varnum SM, Zangar RC.

Stat Appl Genet Mol Biol. 2008;7(1):Article21. doi: 10.2202/1544-6115.1364. Epub 2008 Jul 14.

PMID:
18673290
29.

Immobilization strategies for single-chain antibody microarrays.

Seurynck-Servoss SL, Baird CL, Miller KD, Pefaur NB, Gonzalez RM, Apiyo DO, Engelmann HE, Srivastava S, Kagan J, Rodland KD, Zangar RC.

Proteomics. 2008 Jun;8(11):2199-210. doi: 10.1002/pmic.200701036.

PMID:
18452230
30.

Development and validation of sandwich ELISA microarrays with minimal assay interference.

Gonzalez RM, Seurynck-Servoss SL, Crowley SA, Brown M, Omenn GS, Hayes DF, Zangar RC.

J Proteome Res. 2008 Jun;7(6):2406-14. doi: 10.1021/pr700822t. Epub 2008 Apr 19.

PMID:
18422355
31.

The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability.

Zangar RC, Bollinger N, Verma S, Karin NJ, Lu Y.

Mol Pharmacol. 2008 Jun;73(6):1652-8. doi: 10.1124/mol.107.043976. Epub 2008 Mar 11.

PMID:
18334598
32.

Evaluation of surface chemistries for antibody microarrays.

Seurynck-Servoss SL, White AM, Baird CL, Rodland KD, Zangar RC.

Anal Biochem. 2007 Dec 1;371(1):105-15. Epub 2007 Jul 25.

33.

Surface chemistries for antibody microarrays.

Seurynck-Servoss SL, Baird CL, Rodland KD, Zangar RC.

Front Biosci. 2007 May 1;12:3956-64. Review.

PMID:
17485349
34.

ProMAT: protein microarray analysis tool.

White AM, Daly DS, Varnum SM, Anderson KK, Bollinger N, Zangar RC.

Bioinformatics. 2006 May 15;22(10):1278-9. Epub 2006 Apr 4.

PMID:
16595561
35.

ELISA microarray technology as a high-throughput system for cancer biomarker validation.

Zangar RC, Daly DS, White AM.

Expert Rev Proteomics. 2006 Feb;3(1):37-44. Review.

PMID:
16445349
36.

Studying cellular processes and detecting disease with protein microarrays.

Zangar RC, Varnum SM, Bollinger N.

Drug Metab Rev. 2005;37(3):473-87. Review.

PMID:
16257831
37.

A proteomic study of the HUPO Plasma Proteome Project's pilot samples using an accurate mass and time tag strategy.

Adkins JN, Monroe ME, Auberry KJ, Shen Y, Jacobs JM, Camp DG 2nd, Vitzthum F, Rodland KD, Zangar RC, Smith RD, Pounds JG.

Proteomics. 2005 Aug;5(13):3454-66.

38.

Evaluating concentration estimation errors in ELISA microarray experiments.

Daly DS, White AM, Varnum SM, Anderson KK, Zangar RC.

BMC Bioinformatics. 2005 Jan 26;6:17.

39.
40.

Mechanisms that regulate production of reactive oxygen species by cytochrome P450.

Zangar RC, Davydov DR, Verma S.

Toxicol Appl Pharmacol. 2004 Sep 15;199(3):316-31. Review.

PMID:
15364547
41.

Interactions of phospholipase D and cytochrome P450 protein stability.

Zangar RC, Fan YY, Chapkin RS.

Biochem Pharmacol. 2004 Aug 1;68(3):503-12.

PMID:
15242816
42.

A protein microarray ELISA for screening biological fluids.

Varnum SM, Woodbury RL, Zangar RC.

Methods Mol Biol. 2004;264:161-72.

PMID:
15020788
43.

Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor alpha.

Chen WN, Woodbury RL, Kathmann LE, Opresko LK, Zangar RC, Wiley HS, Thrall BD.

J Biol Chem. 2004 Apr 30;279(18):18488-96. Epub 2004 Feb 20.

44.

Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate.

Kimzey AL, Weitz KK, Guengerich FP, Zangar RC.

Biochemistry. 2003 Nov 4;42(43):12691-9.

PMID:
14580217
45.

Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer.

Varnum SM, Covington CC, Woodbury RL, Petritis K, Kangas LJ, Abdullah MS, Pounds JG, Smith RD, Zangar RC.

Breast Cancer Res Treat. 2003 Jul;80(1):87-97.

PMID:
12889602
46.

Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA.

Woodbury RL, Varnum SM, Zangar RC.

J Proteome Res. 2002 May-Jun;1(3):233-7.

PMID:
12645900
47.

Suppression of cytochrome P450 3A protein levels by proteasome inhibitors.

Zangar RC, Kocarek TA, Shen S, Bollinger N, Dahn MS, Lee DW.

J Pharmacol Exp Ther. 2003 Jun;305(3):872-9. Epub 2003 Mar 6.

PMID:
12626652
48.

Cytochrome P450 3A conjugation to ubiquitin in a process distinct from classical ubiquitination pathway.

Zangar RC, Kimzey AL, Okita JR, Wunschel DS, Edwards RJ, Kim H, Okita RT.

Mol Pharmacol. 2002 Apr;61(4):892-904. Erratum in: Mol Pharmacol. 2003 May;63(5):1198.

PMID:
11901229
49.

Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment.

Kim H, Putt DA, Zangar RC, Wolf CR, Guengerich FP, Edwards RJ, Hollenberg PF, Novak RF.

Drug Metab Dispos. 2001 Mar;29(3):353-60.

PMID:
11181506
50.

Supplemental Content

Loading ...
Support Center